1. Home
  2. RENX vs GRI Comparison

RENX vs GRI Comparison

Compare RENX & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

N/A

Current Price

$0.17

Market Cap

2.0M

Sector

N/A

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$0.22

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RENX
GRI
Founded
2021
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
1.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RENX
GRI
Price
$0.17
$0.22
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.00
AVG Volume (30 Days)
17.5M
4.5M
Earning Date
02-22-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,970,752.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2770.15
N/A
52 Week Low
$0.16
$0.19
52 Week High
$2.74
$13.09

Technical Indicators

Market Signals
Indicator
RENX
GRI
Relative Strength Index (RSI) N/A 23.46
Support Level N/A $0.19
Resistance Level N/A $0.34
Average True Range (ATR) 0.00 0.05
MACD 0.00 0.05
Stochastic Oscillator 0.00 16.91

Price Performance

Historical Comparison
RENX
GRI

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: